NRAS mutations constitute 15–20% of all melanomas and are the most important sub‐group of BRAF WT melanomas, yet therapeutic options for NRAS‐mutant melanoma are still limited (Muñoz‐Couselo et al, 2017). Here, NRAS is linked to melanoma.